Navigation Links
Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344
Date:3/6/2012

id loss of cellular energy and leads to the inhibition of both mammalian target of rapamycin (mTOR1 and mTOR2) pathways. In April 2011, Ayesha Alvero, M.D., Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine, presented data at the American Association for Cancer Research Annual Meeting from a pre-clinical study of NV-128 demonstrating its ability to induce mitochondrial instability, ultimately leading to cell death in otherwise chemotherapy-resistant ovarian cancer stem cells. These results were later published in the August 2011 issue of Molecular Cancer Therapeutics. In additional pre-clinical studies, ME-344 has demonstrated far superior anti-tumor activity against a broad range of human cancer cell lines compared to NV-128.

About Marshall Edwards
Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company's lead drug candidates, ME-143 and ME-344, have been shown to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism, a function critical for cancer cell survival. Marshall Edwards initiated a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors in September 2011 and expects to collect final safety and pharmacokinetic data from the trial by June 2012. The Company submitted an Investigational New Drug application for ME-344 in March 2012 and plans to initiate a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors following approval by the FDA. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards CEO to Present at Roth Capital Partners Growth Stock Conference
2. Marshall Edwards Announces Rights Offering to Stockholders
3. Marshall Edwards Adds $2 Million in Private Placement
4. Marshall Edwards Announces $2 Million Private Placement
5. Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
6. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
7. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
8. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
9. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
10. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
11. Marshall Edwards Announces Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Pharma IQ, after ... successful Serialisation Countdown calendar to cover the years 2014 ... pharmaserialisation.com shows the serialisation requirements around the globe ... into force. For companies dealing with international ... but "when" they will have to comply with new ...
(Date:9/18/2014)... 2014 MiMedx Group, Inc. (NASDAQ: ... marketer of patent protected regenerative biomaterials and bioimplants ... it has entered into a distribution agreement with ... its dehydrated human amnion/chorion membrane ("dHACM") allograft products ... a private label basis. The MiMedx ...
(Date:9/18/2014)... 2014  Zacks.com announces the list of stocks featured ... Research analysts discuss the latest news and events impacting ... the blog include the Avanir Pharmaceuticals (Nasdaq: AVNR - ... Free Report ), Orexigen (Nasdaq: OREX - Free ... ) and Gilead (Nasdaq: GILD - Free Report ...
Breaking Medicine Technology:Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6
(Date:9/18/2014)... It’s been just a few short weeks since ... splint to website visitors, but already the response has been ... delighted. It is perfect and I find it sooo much ... YOU FOR LISTENING!!!" Another user compared the original design ... to slip to the end of my toe. Now that ...
(Date:9/18/2014)... LAKE, Wis. (PRWEB) September 18, 2014 It ... and engage in health and wellness. Once again, Evensong ... in Spa Week by offering three services at a special ... Evensong Spa, managed by Marcus Hotels & Resorts , ... a national event encouraging Americans to embrace health and wellness ...
(Date:9/18/2014)... 2014 (HealthDay News) -- Daily supplements of selenium or ... development of age-related cataracts among men, a new study ... or both could help prevent cataracts. To investigate this ... Harvard Medical School in Boston, and his colleagues examined ... vitamin E. The trial was initially designed to study ...
(Date:9/18/2014)... In 2003, the government ... Barrio Adentro), which it hoped would increase ... Section 6.1.3.). In 2009, it invested VEF28 ... of Pharmaceutical Elaborations (Servicio Autónomo de Elaboraciones ... at a cheaper rate than private pharmaceutical ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Qualis Health, ... has published a white paper, “Advancing Primary Care ... Health Information Technology.” , Authors Jeff Hummel, MD, ... provide guidance to organizations engaged in the work of ... health IT can bolster PCMH objectives, such as generating ...
Breaking Medicine News(10 mins):Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2
... Reduce Stiffness for Better Health with,Innovative ,Sleep and ... FORT LAUDERDALE, Fla., Jan. 9 Contour ... people implement an,ergonomic makeover into their life for ... well being. By aligning the body, relieving,pressure points ...
... Makes Available New Daily Dosing Option for the Treatment ... and Company,(NYSE: LLY ) announced today that the ... for once daily use (2.5 mg and,5 mg), an ... dysfunction,(ED). When Cialis for once daily use is taken ...
... private equity, public offering, ... Irell represents leading clients in gaming, green tech, ... construction, LOS ANGELES, Jan. 8 Irell & Manella ... corporate deals,valued at more than $7 billion., The firm ...
... years, The Leukemia &,Lymphoma Society has organized "Team ... achieve personal goals and most of all, raised,over ... video from The Leukemia & Lymphoma Society at:, ... In Training" helps,individuals prepare for a full marathon ...
... Red Cross,announced today that J. Chris Hrouda has ... for the organization,s Biomedical Services., Hrouda will ... Each year the American Red Cross collects approximately ... million blood products to,patients at approximately 3,000 hospitals ...
... 8 Conseco, Inc. (NYSE:,CNO) announced that Todd M. ... senior vice president and treasurer. He will report to ... Hacker joins Conseco from YRC Worldwide, where he was ... treasurer from,2004-2005. From 2005-2006, he was senior vice president, ...
Cached Medicine News:Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 2Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 3Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 2Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 3Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 4Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 5Health News:Irell & Manella Posts Strong Year for Corporate Transactions 2Health News:Irell & Manella Posts Strong Year for Corporate Transactions 3Health News:Irell & Manella Posts Strong Year for Corporate Transactions 4Health News:Irell & Manella Posts Strong Year for Corporate Transactions 5Health News:Irell & Manella Posts Strong Year for Corporate Transactions 6Health News:American Red Cross Announces New Leader for Biomedical Services 2
... The best lens available ... trabeculoplasty. One 62 mirror. ... image and laser beam ... be used on most ...
Direct gonioscopy lens with magnification. The lens rests on the scleral flange creating a corneal vault and leaving the anterior chamber angle undisturbed. Three sizes available....
Lacrimal cannula blunt tip with 0.3 mm side port, straight....
West lachrymal cannula, blunt tip with inner side opening, gently curved shaft....
Medicine Products: